Q-omics provides the consensus-scored NOP56 profile across patient tissues and cancer cell-line models. NOP56 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NOP56 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, NOP56 protein abundance shows 27,842 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where NOP56 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOP56 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOP56 survival associations across molecular data types. NOP56 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOP56 RNA expression–survival associations across cancer types. High NOP56 expression shows unfavorable associations in KIRP, LIHC, KIRC, MESO, UVM and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NOP56 RNA expression.
This table summarizes NOP56 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NOP56. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOP56 shows higher tumor expression in COAD, KIRC, HNSC, KIRP, BLCA and STAD. The COAD box plot shows higher NOP56 RNA expression in tumor versus normal tissue (log2 FC = +1.822, t-test p < 0.001).
This table shows molecular features associated with NOP56 in patient tissues and cancer cell lines. In patient samples, NOP56 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NOP56 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
